Physician profile
Usha Seth
NPI 1982778841
$5,423.23
in general payments reported to CMS, 2019-2025
24 companies · $423 in 2025
The $423 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $968 · 2020: $770 · 2021: $582 · 2022: $551 · 2023: $1,188 · 2024: $942 · 2025: $423.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,553.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,552.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,154.84 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $774.32 | 2019-2025 | Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $445.12 | 2019-2025 | Trelegy Ellipta |
| Pfizer INC. | $440.25 | 2019-2024 | |
| Lilly USA, LLC | $440.23 | 2019-2024 | Mounjaro, Emgality, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $262.52 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $252.46 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $247.13 | 2019-2023 | Verquvo |
| Janssen Pharmaceuticals, INC | $191.40 | 2019-2021 | |
| Amarin Pharma, INC. | $166.84 | 2020-2021 | |
| Astellas Pharma US INC | $154.91 | 2019-2024 | Veozah, Myrbetriq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $145.07 | 2019-2025 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $131.19 | 2023-2024 | Rexulti |
| Eisai INC. | $99.95 | 2024-2025 | |
| Abbott Laboratories | $99.18 | 2022-2023 | Proclaim |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $92.42 | 2019 | |
| Vanda Pharmaceuticals INC. | $81.52 | 2023 | Hetlioz |
| Exact Sciences Corporation | $79.39 | 2023-2024 | Cologuard Collection Kit |
| Amgen INC. | $59.06 | 2020-2025 | Otezla, Repatha |
| Lundbeck LLC | $26.48 | 2025 | Rexulti |
| Abbvie INC. | $25.84 | 2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $22.23 | 2025 | Caplyta |
| Phathom Pharmaceuticals, INC. | $18.12 | 2024 | Voquezna |
| Allergan, INC. | $12.76 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Usha Seth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.